Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY2608204 Reference, Glucokinase Activator
LY2608204 · 1 trial · 1 indication
Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.
| Arm | Type | Description |
|---|---|---|
| LY2608204 | EXPERIMENTAL | Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment. |
| Name | Type | Description |
|---|---|---|
| LY2608204 | DRUG | Administered orally. |
Inclusion Criteria: * Patients diagnosed with Type 2 diabetes mellitus (T2DM) who are currently treated with diet/lifestyle measures alone or in combination with anti-diabetic agents, including insulins * Have fasting blood glucose (FBG) greater than or equal to 160 milligram/deciliter (mg/dL), wit...
LY2608204 is an investigational small molecule developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It is a glucokinase (GCK) activator that has been studied in early-stage clinical research. The compound is not approved for any indication and remains in Phase 1 development.
LY2608204 was studied as a potential treatment for type 2 diabetes mellitus, a metabolic condition characterized by elevated blood glucose. It was evaluated in a Phase 1 trial in patients with type 2 diabetes. It is investigational and has not been approved for the treatment of type 2 diabetes or any other condition.
LY2608204 targets glucokinase (GCK) and acts as a glucokinase activator. Glucokinase is an enzyme involved in glucose metabolism, and activators of this target are studied for their potential to influence blood glucose regulation in type 2 diabetes. The drug is a small molecule developed by Eli Lilly and Company.
LY2608204 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company sponsored the Phase 1 clinical trial of the compound in patients with type 2 diabetes. Development remains at the Phase 1 stage.
LY2608204 is in Phase 1 clinical development. It is an investigational agent and is not FDA approved. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study enrolled 20 patients with type 2 diabetes.
LY2608204 has been evaluated in one completed Phase 1 trial, NCT01247363, titled A Study of LY2608204 in Patients With Type 2 Diabetes. The trial enrolled 20 patients across the United States and Singapore. It was an uncontrolled study without randomization or double blinding, and it is now completed.
LY2608204 Reference is an alternative name used for LY2608204, the investigational glucokinase activator developed by Eli Lilly and Company for type 2 diabetes. Both names refer to the same small molecule compound, which has been studied in a single completed Phase 1 trial.